Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals

Table 2 Manuscripts included in qualitative evidence review (n = 814 individuals in 18 studies)

First author	Year	Location	Study design	Sample size (n)	Sample population	Treatment methods
Harris	2009	Australia	Interviews^a	40	Former PWID seeking care	Interferon + ribavirin
Harris	2013	United Kingdom	Interviews	49	Current and former PWID and providers	Interferon + ribavirin
Hopwood	2007	Australia	Interviews	20	Patients and providers from a HCV treatment center	Interferon-based, unspecific
Munoz Plaza	2008	USA	Interview, Focus groups	164	Patients enrolled in drug treatment programs	Interferon + ribavirin (not all patients on treatment)
Nguyen	2007	Australia	Personal narratives	3	Patients enrolled in PEG-IFN treatment study	Interferon OR interferon + ribavirin if HIV/HCV co-inf
Norman	2008	Australia	Interviews, Focus groups	10	Current or former PWID seeking care or working at HCV treatment center	Interferon + ribavirin
Strauss	2005	USA	Interviews, Focus groups	72	Patients and staff in a drug treatment programs	Interferon + ribavirin
Treloar	2008	Australia	Interviews	77	Current and former drug treatment patients	Interferon only (n = 2)
Treloar	2013	Australia	Interviews	76	HCV patients receiving opiate-substitution treatment	Interferon + ribavirin
Rasi	2014	Switzerland	Interviews	14	HCV patients undergoing protease-inhibitor therapy	DAA triple therapy (Protease inhibitor, interferon, ribavirin)

Abbreviations: PWID people who inject drugs, HCV hepatitis C virus, PEG-IFN pegylated interferon
^aInterviews refer to one-on-one, in-depth interviews

ISSN: 1471-2458